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S U M M A R Y
Objectives: To analyze the epidemiology and laboratory characteristics of Staphylococcus aureus
bacteremia (SAB) in an Indian tertiary care hospital.
Methods: We collected clinical, epidemiological, and laboratory data of all cases of SAB during August
2010 through July 2011. All isolates were tested for the Panton–Valentine leukocidin (PVL) gene.
Results: Eighteen percent of all blood stream infections (BSIs) were attributable to S. aureus. Among a
total of 70 cases of SAB, 54% were due to methicillin-resistant S. aureus (MRSA) and 46% to methicillin-
susceptible S. aureus (MSSA). Seventy-four percent of the cases had community-acquired (CA) SAB,
among whom 69% had been hospitalized previously. Skin and soft tissue infections (SSTI) (30%) and
respiratory infections (24%) were the common sources of bacteremia. The overall case fatality rate was
27%, and a similar percentage (23%) of patients discontinued therapy due to a poor medical outcome. The
PVL gene was detected in 16% of S. aureus isolates, predominantly in CA-S. aureus (82%). SSTIs and
pneumonia were the common sources of bacteremia in 45% of patients infected with a PVL-positive
strain.
Conclusions: S. aureus is a signiﬁcant cause of BSI with a case fatality rate comparable to those of other
developing nations. The upsurge in MRSA rates is alarming in our setup. Antibiotic stewardship and strict
control of antibiotic use must be implemented by health care professionals to curb the increasing trend
in MRSA BSIs.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Among Gram-positive bacteremia, Staphylococcus aureus
bacteremia (SAB) is one of the most prevalent and difﬁcult to
treat infections and is associated with signiﬁcant morbidity and
mortality.1 The incidence of SAB and complications such as
endocarditis are rising sharply due to an increase in frequency of
invasive surgery, increased use of intravascular devices, and an
increased number of immune-compromised patients.2 SAB has§ This study was presented in part as a poster titled ‘‘Upsurge of MRSA bacteremia
in South Indian tertiary care hospital – an observational study on clinical
epidemiology and resistance proﬁle’’ at the 15th International Congress on
Infectious Diseases (ICID), Bangkok, Thailand, June 13–16, 2012.
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http://dx.doi.org/10.1016/j.ijid.2013.06.002gained considerable prominence due to its varied epidemiology
between countries, the increase in rates of infection caused by
methicillin-resistant S. aureus (MRSA), increased treatment
costs, and disease complications. Further, the emergence and
spread of community-acquired MRSA (CA-MRSA) and its ability
to cause serious invasive infections is a major public health
concern.1–4 However, most of the published reports originate
from developed nations, and data from Asian countries are
grossly underrepresented. In the face of emerging multi-
resistant organisms, timely information about disease epidemi-
ology is needed to guide appropriate therapy. On the Indian
subcontinent, diversity in the health care system and a lack of
resources are major hurdles in obtaining relevant clinical and
demographic data to establish the burden of disease due to S.
aureus accurately. The present study was undertaken to
investigate the clinical epidemiology, treatment, outcome,ses. Published by Elsevier Ltd. All rights reserved.
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tertiary care center of southern India.
2. Methods
2.1. Setting
The present study was carried out in a 2000-bed tertiary care
hospital during August 2010 through July 2011. The study included
all patients admitted to hospital who presented an episode of SAB.
2.2. Study design and patients
A prospective observational cohort study was conducted on
patients of any age admitted to various clinical specialties with at
least one clinically signiﬁcant growth of S. aureus in blood culture.
Details of patient demographics, clinical characteristics, comor-
bidities, course of illness, treatment, and outcome were recorded.
Sources of infections leading to SAB were determined based on
clinical ﬁndings and isolation of S. aureus from other anatomical
sites. Epidemiological classiﬁcation was used to deﬁne the
acquisition of infection. Infections were deﬁned as community-
acquired (CA) if blood culture was done at 48 h of admission and
clinical symptoms were consistent with an invasive S. aureus
infection, and as hospital-acquired (HA) if blood culture was done
at >48 h of admission.5
Screening of patients for MRSA carrier status is not a mandatory
practice in our hospital, and hence tests were performed only upon
request of the treating clinician.
2.3. Microbiological procedures and data
Blood culture was done using BacT/ALERT FA bottles (bioMe´r-
ieux, Marcy l’Etoile, France). Growth of S. aureus was identiﬁed
based on standard laboratory procedures.6 Antimicrobial suscep-
tibility was tested in accordance with Clinical and Laboratory
Standards Institute (CLSI) guidelines by Kirby–Bauer disk diffusion
method 7. Cefoxitin disk diffusion was used to categorize S. aureus
isolates as MRSA or MSSA.7 All of the isolates were tested for the
presence of the Panton–Valentine leukocidin (PVL) gene by a
protocol described previously.8 A 433-bp product was visualized
by electrophoresis in agarose gel stained with ethidium bromide. A
PVL-positive S. aureus strain was used as positive control in each
run. Results of concomitant cultures that grew S. aureus, such as
catheter culture and culture of respiratory secretions and pus, were
collected from the records.
2.4. Statistical analysis
The data analysis was performed using SPSS software version
15 (SPSS Inc., Chicago, IL, USA). Data were summarized using
percentages. Risk was estimated using the odds ratio (OR) with 95%
conﬁdence interval (95% CI). The relative risk with 95% CI was
obtained for the case fatality and the adverse outcomes. The
associations between various patient characteristics and MRSA
status were studied using the Chi-square test. The median and
interquartile range (IQR) were used to summarize the data on
duration of treatment and hospital stay. A comparison of the
duration of hospital stay and treatment was done using the Mann–
Whitney test. A p-value below 0.05 was considered to be
statistically signiﬁcant.
3. Results
A total of 70 patients with SAB were studied, comprising 51
(73%) males and 19 (27%) females. The incidence of SAB was 1.44/1000 admissions. Eighteen percent of all blood stream infections
(BSIs) were attributable to S. aureus; this was the second most
common cause of bacteremia after Escherichia coli (32%). The age of
the patients ranged between 0 and 76 years, with a median of 44
years (IQR 27.75–60.50). Demographic details, risk factors, and co-
morbidities of the patients are presented in Table 1.
MRSA accounted for 54% (n = 38) of SAB, while 46% (n = 32) was
due to MSSA. According to the deﬁnitions used in this study, the
majority of cases (n = 52, 74%) were community-acquired (CA-
SAB), of which 27 (52%) were due to MRSA (CA-MRSA). Among CA-
SAB cases, 36 of 52 (69%) had a health care-associated risk factor in
the form of previous hospitalization in the last 1 year. Previous
hospitalization was a signiﬁcant risk factor for acquiring CA-MRSA
infections. In the subgroup of CA-MRSA infections, 22 of 27 (81%)
had been hospitalized previously compared to 14 of 25 (56%) CA-
MSSA infections (OR 3.5, 95% CI 1–12.1; p = 0.047). Details of
antibiotic consumption and health care risk factors could not be
obtained. Among intensive care unit admissions with SAB, 66%
were attributed to those with MRSA infections.
The sources of infection, clinical characteristics, treatment, and
outcome of patients with SAB are given in Table 2. Endocarditis
(7%) was not a common complication in our study. Apart from the
three patients with clinical evidence of endocarditis, two more
patients were found to have a vegetation by transthoracic
echocardiography. Intravenous catheter-related infections con-
tributed to 55% of HA-SAB infections, of which 36% were due to
MRSA.
Screening for MRSA carriage was done for 76% (n = 29) of MRSA
bacteremia cases, and the prevalence of nasal carriage was found to
be 45% (n = 13). MRSA screening was positive at all four anatomical
sites including the anterior nares, ﬁnger tips, axilla, and groin in
nine (31%) cases.
Anti-staphylococcal empirical therapy was given to a total of 31
(44%) patients, of whom 11 (16%) had received anti MRSA
empirical therapy. Speciﬁc anti-staphylococcal therapy was
initiated after obtaining the culture results in 51 (73%) patients,
while 19 (27%) patients either died or stopped therapy before the
culture results were available due to a poor medical prognosis and
being unable to bear the treatment costs. Vancomycin, linezolid,
and teicoplanin were the anti-MRSA therapy received, and
amoxicillin–clavulanic acid, cefazolin, cloxacillin, and clindamycin
were used to treat MSSA infections. For nine patients with MSSA
infections, anti-MRSA empirical therapy was not de-escalated and
they continued to receive the same therapy.
The time to positivity of blood cultures ranged between 1 and 5
days, with a median of 2 days (standard deviation 0.742). Seven
percent of cultures were ﬂagged as positive in the ﬁrst 24 h, 79%
within 48 h, and 93% within 72 h. Antimicrobial susceptibility results
of S. aureus isolates are shown in Figure 1. Among the MRSA isolates,
30 (79%) were resistant to three or more drugs like ciproﬂoxacin,
amikacin, doxycycline, clindamycin, erythromycin, and trimetho-
prim–sulfamethoxazole. Resistance to all of the non-beta-lactam
antibiotics was seen in 16% of MRSA strains. All the isolates remained
uniformly susceptible to glycopeptides.
The PVL gene was detected in 16% (N=11) of all S. aureus isolates
from BSIs, including nine (82%) CA-S. aureus and two (18%) HA-S.
aureus (both MSSA). Among CA-S. aureus strains, 17% had PVL
positivity. Details of the characteristics of patients, onset of
infection, and outcome are shown in Table 3. The most common
source of infection in those with PVL-positive strains was skin and
soft tissue infection (SSTI; 27%), followed by pneumonia (18%).
Among the patients who received anti-staphylococcal therapy
(51, 73%), an adverse outcome (death or loss to follow-up) was
observed in 16 (31%). More CA-SAB patients showed an adverse
outcome compared to HA-SAB patients (n = 27, 52% vs. n = 8, 44%;
relative risk 1.1, 95% CI 0.8–1.4; p = 0.584). An adverse outcome
Table 1
Demographics and baseline characteristics of patients with SAB
Study variables All SAB cases
n (%) (n = 70)
MRSA bacteremia
n (%) (n = 38)
MSSA bacteremia
n (%) (n = 32)
OR (95% CI) p-Value
Gender
Male 51 (73) 27 (71) 24 (75) 0.8 (0.3, 2.4) 0.711
Female 19 (27) 11 (29) 8 (25)
Age category
Neonates 6 (9) 3 (8) 3 (9) Pediatric vs. adult 1.4 (0.4, 4.9) 0.596
1–18 years 7 (10) 5 (13) 2 (6) Neonate vs. pediatric 0.4 (0.1, 4.0) 0.592
19–59 years 40 (57) 22 (58) 18 (56)
60 years 17 (24) 8 (21) 9 (28)
Clinical specialties
Medical 31 (44)
Nephrology 7 (10)
Neonatology 6 (9)
Pediatrics 5 (7)
Surgery 4 (6)
Cardiology 4 (6)
Orthopedics 3 (4)
Others 10 (14)
Acquisition of infection
Community-acquired 52 (74) 27 (52) 25 (48) 0.7 (0.2, 2.1) 0.589
Hospital-acquired 18 (26) 11 (61) 7 (39)
ICU 35 (50) 23 (61) 12 (38) 2.6 (1.0, 6.7) 0.055
Non-ICU 35 (50) 15 (39) 20 (63)
Risk factors
Previous hospitalization in last year 49 (70) 29 (76) 20 (62) 1.9 (0.7, 5.4) 0.209
Previous antibiotic therapy in last 3 months 57 (81) 32 (91) 25 (80)
Hemodialysis 7 (10) 4 (11) 3 (9) 1.2 (0.2, 5.5) 0.689
Co-morbidities
Diabetes mellitus 28 (40) 14 (37) 14 (44) 0.8 (0.3, 2.0) 0.557
Hypertension 19 (27) 9 (24) 10 (31) 0.7 (0.2, 2.0) 0.478
Chronic kidney disease 7 (10) 4 (11) 3 (9) 1.2 (0.2, 5.5) 0.873
Malignancy 4 (6) 3 (8) 1 (3) 2.5 (0.3, 25.4) 0.620
Cirrhosis 7 (10) 2 (5) 5 (16) 0.3 (0.1, 1.7) 0.234
Carrier status (n = 29) 13 (45) -
SAB, Staphylococcus aureus bacteremia; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; OR, odds ratio; CI, conﬁdence interval; ICU, intensive
care unit.
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in 47% of those with a PVL-negative S. aureus infection.
4. Discussion
This is the ﬁrst observational report from India encompassing
the clinical epidemiology, antimicrobial resistance, and virulence
determinants of SAB in a tertiary care hospital setup. SAB
contributed to 18% of total bacteremia cases, whereas Gram-
negative bacteria had a considerable share of 75%. In 2002, a report
from the same center showed a 19% prevalence of SAB amongTable 2
Clinical characteristics, treatment, and outcome of patients with SAB
Study variables All SAB cases
n (%) (n = 70)
Source of infection
Skin and soft tissue infection 21 (30) 
Respiratory infection 17 (24) 
Intravascular catheter infection 11 (16) 
Bone and joint infection 10 (14) 
Central nervous system infection 2 (3) 
Unknown 9 (13) 
Complications
Sepsis 22 (31) 
Endocarditis 3 (4) 
Treatment duration, median (IQR) days 14 (12–28) 
Length of hospitalization, median (IQR) days 14 (5.75–23) 
Case fatality 19 (27) 
Adverse outcome (case fatality + discharged before therapy) 35 (50) 
PVL gene 11 (16) 
SAB, Staphylococcus aureus bacteremia; MRSA, methicillin-resistant S. aureus; MSSA
interquartile range; PVL, Panton–Valentine leukocidin.high-risk patients.9 Two more studies from northern India
reported 13.86% prevalence of SAB among all BSIs and 29%
prevalence in nosocomial bacteremia.10,11 Similar ﬁndings are
observed in Latin America, the USA, Europe, and Australia, with
rates of SAB ranging from 16.5% to 25%.3,12–14 Among a very few
contemporary reports from Asia, Philippines showed a prevalence
of 7.4%, Malaysia 10.4%, and Laos 19%.15–17
MRSA constituted 54% of all SAB episodes in our study. These
results are similar to those of a US surveillance network report.18
However, European countries have shown a wide range of MRSA
proportions (0% in Iceland to 52.4% in Malta) and a few countriesMRSA bacteremia
n (%) (n = 38)
MSSA bacteremia
n (%) (n = 32)
OR (95% CI) p-Value
13 (34) 8 (25) 1.6 (0.6, 4.4) 0.443
11 (30) 6 (19) 1.8 (0.6, 5.5) 0.406
4 (11) 7 (22) 0.4 (0.1, 1.6) 0.323
7 (18) 3 (9) 2.2 (0.5, 9.3) 0.326
- 2 (6)
5 (13) 4 (13) 1.1 (0.3, 4.3) 1.000
14 (37) 8 (26) 1.8 (0.6, 5.0) 0.314
2 (5) 1 (3) 1.7 (0.2, 20.0) 0.234
14 (14–40) 14 (10–14) 1.1 (0.95, 1.2) 0.221
16.5 (6.75–25.75) 12 (4–20) 1.02 (0.98, 1.05) 0.348
12 (32) 7 (22) 1.3 (0.8, 1.9) 0.426
20 (53) 15 (47) 1.1 (0.7, 1.7) 0.811
4 (11) 7 (25) 0.4 (0.3, 1.4) 0.323
, methicillin-susceptible S. aureus; OR, odds ratio; CI, conﬁdence interval; IQR,
Table 3
Characteristics of patients with PVL-positive Staphylococcus aureus infection
No. Age, years Gender Isolate Acquisition Focus of infection Outcome Previous hospitalization
1 62 M MSSA Hospital Intravascular catheter infection Recovered Yes
2 11 F MRSA Community Osteomyelitis Recovered No
3 55 M MSSA Community Cellulitis Died Yes
4 32 M MSSA Community Unknown Left before therapy Yes
5 70 M MRSA Community Pneumonia Died Yes
6 73 M MSSA Hospital Intravascular catheter infection Recovered Yes
7 19 F MSSA Community Orbital cellulitis Recovered No
8 64 F MRSA Community Pneumonia Died Yes
9 57 M MSSA Community Unknown Left before therapy Yes
10 65 M MRSA Community Unknown Died Yes
11 54 M MSSA Community Multiple cutaneous abscesses Died Yes
PVL, Panton–Valentine leukocidin; M, male; F, female; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus.
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MRSA rates over recent years due to the implementation of
multifaceted prevention programs.14,19,20 The rapid reduction in
MRSA in the UK was achieved due to a nationwide intervention
based on audit and quality improvement. A population-based
surveillance for SAB in Canada showed an MRSA prevalence of 11%,
while hospital-based studies in Australia and Thailand showed 26%
and 29% prevalence of MRSA, respectively.3–5 Within India, very
few reports are available to throw light on the epidemiology of
SAB. A study from northeastern India showed a 9% prevalence of
SAB comprising 11% MRSA among pediatric patients.21 Within-
country variations in proportions of MRSA in SAB could be
explained by the population under study and the size, standards of
care, and local epidemiology of the hospitals.
A few important epidemiological observations were made in
our study. CA infections outnumbered HA infections (74% vs. 26%)
and the proportion of MRSA was high in CA-SAB (52%) when the
timing of blood culture collection was used as a criterion for
categorization of CA- and HA-SAB. These results appear very
different from those of developed nations where one third of SAB
episodes have been found to be health care-associated.3,5,22
However, 51% of those with CA-SAB infections had health care-
associated risk factor like previous hospitalization, thus reducing
the rates of true community onset SAB to 23%. Molecular typing to
characterize the isolates into CA or HA was not done in our study. It
might very well be possible that a few of the cases of CA-MRSA
originated from health care settings and that this currently
circulates in the community. Population-based studies, clearer
information on the health-seeking behavior of patients, surveil-
lance, and audits are needed to obtain precise information on
transmission dynamics of the bacteria and to clarify the
uncertainties about acquisition of MRSA in the community.
The range of clinical manifestations was similar to those
identiﬁed in other studies. However we found a lower prevalenceFigure 1. Antimicrobial susceptibility of Staphylococcus aureus isolates causing
blood stream infections (data in percentage susceptibility).(7%) of endocarditis, either as a complication or as a primary
manifestation of SAB, in our study subjects compared to published
reports.4,5 Clinical evidence of endocarditis was seen in three cases
(4%) of SAB, while the use of transthoracic echocardiography
detected two more patients with vegetations on the cardiac valves.
The routine use of transesophageal echocardiography, which is not
currently a practice in our setting, might have detected a few more
cases of endocarditis due to S. aureus.23
Estimates of the case fatality of MRSA and MSSA bacteremia in
our study are higher than those from developed nations,3,24,25 but
are similar to reports from Thailand.4 A substantial proportion of
patients with SAB (27%) could not beneﬁt from therapy because of
death or discharge before culture results were available. This
would further increase the proportion of adverse outcome among
patients with SAB. We could not establish an association between
various risk factors and case fatality due to the small number of
subjects. No signiﬁcant difference in fatality among MRSA and
MSSA bacteremia was shown, similar to the ﬁndings of another
report.26 While debate continues on the inﬂuence of MRSA
infection on mortality, a meta-analysis of 31 studies has clearly
demonstrated a signiﬁcant increase in mortality associated with
MRSA bacteremia compared with MSSA bacteremia.27
The high resistance of S. aureus isolates to ciproﬂoxacin and
erythromycin points towards restraining the routine use of these
drugs in the treatment of CA pneumonia and SSTIs of suspected
staphylococcal etiology in primary and secondary care centers.
Increasing rates of MRSA infections and resistance to multiple non-
beta-lactam antibiotics raises concerns over the choice of
empirical therapy of suspected staphylococcal infections among
patients of all age groups in our setup.
The presence of the PVL virulence gene is associated with
increased disease severity in S. aureus infections ranging from
cutaneous infections to chronic osteomyelitis and severe necro-
tizing pneumonia.28–31 Despite the presumed importance of the
PVL gene, few data are available on strains causing BSIs. A lower
prevalence (0.9% and 1.4%) of the PVL gene has been reported in a
few studies on BSIs.32–34Wang et al. reported PVL gene positivity of
58% among CA-MRSA isolates from BSIs.26 We report for the ﬁrst
time in India, the occurrence and prevalence of the PVL gene
among SAB infections. Our study demonstrates 16% prevalence of
the PVL gene in all SAB infections and 15% among CA-MRSA
infections. Interestingly, three of the four patients with PVL-
positive CA-MRSA infections had been hospitalized previously. The
focus of infection among these patients is in agreement with the
published reports.28–31,35,36 Though the virulence gene is not a
predictor of the occurrence of bacteremia in these localized
infections, early interventions are needed to prevent deadly
complications. We also found an increased case fatality among
patients with PVL-positive S. aureus infections.
Our study has several limitations due to the observational study
design. We could not establish associations between several risk
V.K. Eshwara et al. / International Journal of Infectious Diseases 17 (2013) e1051–e1055 e1055factors and outcome measures in various patient categories such as
CA- and HA-MRSA and MSSA infections because of the lack of
power. Details of the acquisition of infection and association
between various health-seeking behaviors of the patients could
not be elucidated due to the non-availability of appropriate
records. Molecular characterization of the isolates and epidemio-
logical typing were not performed.
The ﬁndings of this study establish S. aureus as a signiﬁcant
pathogen in BSIs in the Indian subcontinent, with high rates of
MRSA infections both in community and hospital settings causing
signiﬁcant morbidity and mortality. Early diagnosis and interven-
tions including surgical drainage would prevent an adverse
outcome when the focus of infection is evident and suggestive
of a staphylococcal origin. Carrier screening at admission and
decolonization therapy remain controversial in resource-limited
countries. The use of the European model of antibiotic stewardship
and the control of antibiotic use should be the preferred long-term
strategy to control MRSA infections. The combined efforts of
infection control practitioners, microbiologists, and public health
professionals are needed to limit the spread of MRSA infections
beyond the conﬁnes of the hospital.
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